https://staging.lamerie.com/blog/ 2019-01-08T17:37:47+00:00 https://staging.lamerie.com/anti-inflammatory-and-cancer-antibodies-make-out-65-of-the-innovator-biologics-market-in-2025/ 2026-03-10T10:15:07+00:00 https://staging.lamerie.com/pipeline-of-muc16-targeted-immunotherapy/ 2025-11-10T10:11:57+00:00 https://staging.lamerie.com/pipeline-of-cdh6-targeted-immunotherapy/ 2025-11-08T15:53:13+00:00 https://staging.lamerie.com/pipeline-of-muc1-targeted-immunotherapy/ 2025-11-06T11:53:24+00:00 https://staging.lamerie.com/pipeline-of-claudin-18-2-targeted-immunotherapy/ 2025-09-25T09:03:51+00:00 https://staging.lamerie.com/pipeline-of-pd-l1-x-4-1bb-cd137-bispecific-antibodies/ 2025-09-24T11:56:48+00:00 https://staging.lamerie.com/pipeline-of-cd47-and-sirp-alpha-targeted-immunotherapy/ 2025-09-23T16:42:27+00:00 https://staging.lamerie.com/pipeline-of-complement-c5-inhibitors-c5-receptor-antagonists/ 2025-09-22T12:38:30+00:00 https://staging.lamerie.com/pipeline-of-interleukin-6-il-6-receptor-antagonists-and-il6-inhibitors/ 2025-09-09T11:15:50+00:00 https://staging.lamerie.com/pipeline-of-cd40-agonists-and-cd40-l-antagonists/ 2025-09-09T07:56:27+00:00 https://staging.lamerie.com/pipeline-of-cd73-inhibitors/ 2025-09-08T09:32:59+00:00 https://staging.lamerie.com/pipeline-of-igf-1r-and-igf-1-targeted-immunotherapy/ 2025-09-05T09:53:22+00:00 https://staging.lamerie.com/pipeline-of-napi2b-targeted-antibody-drug-conjugates/ 2025-09-04T13:15:26+00:00 https://staging.lamerie.com/pipeline-of-fcrn-targeted-therapies/ 2025-09-03T09:58:36+00:00 https://staging.lamerie.com/customized-pipeline-review-of-immunotherapies-against-customer-selected-target/ 2025-09-01T08:30:01+00:00 https://staging.lamerie.com/pipeline-of-klk2-targeted-immunotherapies/ 2025-08-31T08:16:33+00:00 https://staging.lamerie.com/in-vivo-expression-of-antibodies-the-coming-of-age-of-a-further-antibody-drug-modality/ 2025-08-30T09:21:14+00:00 https://staging.lamerie.com/pipeline-of-steap1-and-steap2-targeted-immunotherapies/ 2025-08-30T08:33:51+00:00 https://staging.lamerie.com/pipeline-of-tissue-factor-targeted-immunotherapies/ 2025-08-27T15:25:57+00:00 https://staging.lamerie.com/pipeline-of-cd38-targeted-immunotherapies/ 2025-08-26T11:51:21+00:00 https://staging.lamerie.com/pipeline-of-trop-2-targeted-immunotherapies/ 2025-08-26T10:39:28+00:00 https://staging.lamerie.com/pipeline-of-nectin-4-targeted-immunotherapies/ 2025-08-26T09:21:40+00:00 https://staging.lamerie.com/pipeline-of-ccr8-targeted-immunotherapies/ 2025-08-20T08:46:22+00:00 https://staging.lamerie.com/pipeline-of-epcam-targeted-immunotherapies/ 2025-08-19T08:23:17+00:00 https://staging.lamerie.com/pipeline-of-5t4-targeted-immunotherapies-as-an-example-for-new-service-of-pipeline-evaluations/ 2025-08-19T06:57:57+00:00 https://staging.lamerie.com/pipeline-of-b7-h4-targeted-immunotherapies/ 2025-08-18T16:12:10+00:00 https://staging.lamerie.com/pipeline-of-her3-targeted-immunotherapies/ 2025-08-18T16:10:03+00:00 https://staging.lamerie.com/pipeline-of-c-met-targeted-immunotherapies/ 2025-08-18T16:09:36+00:00 https://staging.lamerie.com/pipeline-of-mesothelin-targeted-immunotherapies/ 2025-08-18T16:09:10+00:00 https://staging.lamerie.com/target-selection-in-drug-discovery-new-standardized-service-of-evaluation-of-customer-selected-targets/ 2025-08-14T12:50:25+00:00 https://staging.lamerie.com/wp-content/uploads/2025/08/Image-04.png https://staging.lamerie.com/pipeline-of-b7-h3-targeted-immunotherapy/ 2025-08-05T10:42:54+00:00 https://staging.lamerie.com/pipeline-of-dll3-targeted-immunotherapy/ 2025-08-05T10:42:02+00:00 https://staging.lamerie.com/pipeline-of-glypican-3-gpc3-targeted-therapy/ 2025-08-05T10:41:40+00:00 https://staging.lamerie.com/pipeline-of-fibroblast-activation-protein-fap-targeted-therapy/ 2025-08-05T10:41:15+00:00 https://staging.lamerie.com/pipeline-of-folate-receptor-alpha-fr%ce%b1-targeted-therapy/ 2025-08-05T10:40:51+00:00 https://staging.lamerie.com/pipeline-of-tl1a-inhibitors-dr3-antagonists/ 2025-08-05T10:40:26+00:00 https://staging.lamerie.com/pipeline-of-tslp-inhibitors-and-tslp-receptor-antagonists/ 2025-08-05T10:39:55+00:00 https://staging.lamerie.com/in-vivo-expression-of-antibody-by-dna-or-rna-an-emerging-new-drug-modality-to-overcome-limitations-of-passive-immunotherapy/ 2025-06-28T08:45:08+00:00 https://staging.lamerie.com/innovation-fuels-the-biologics-market-growth-of-therapeutic-antibodies-and-proteins-in-2024/ 2025-03-09T11:45:23+00:00 https://staging.lamerie.com/outstanding-antitumor-activity-of-first-in-class-and-so-far-best-in-class-pd-1xvegf-bispecific-antibody-opens-up-plenty-of-opportunities-for-business-deals-and-better-followers/ 2025-02-23T09:18:29+00:00 https://staging.lamerie.com/degrader-antibody-conjugates-an-emerging-novel-drug-modality-to-address-undruggable-targets/ 2024-09-04T07:10:54+00:00 https://staging.lamerie.com/2023-global-biologics-sales-exceeding-us-300-bln-for-the-first-time/ 2024-03-08T09:15:03+00:00 https://staging.lamerie.com/sales-of-therapeutic-antibodies-and-proteins-in-2022-close-to-us-300-bln-with-antibodies-contributing-more-than-80/ 2023-03-08T10:07:50+00:00 https://staging.lamerie.com/chimeric-antigen-receptor-macrophages-car-m-an-emerging-technology-with-promise-to-improve-efficacy-and-safety-of-tumor-immunotherapy/ 2023-02-10T09:36:14+00:00 https://staging.lamerie.com/emerging-rna-targeted-drug-modalities-open-the-door-for-novel-treatments/ 2022-11-15T13:49:00+00:00 https://staging.lamerie.com/compelling-novel-cancer-targets-with-promise-of-low-on-target-off-tumor-toxicity/ 2022-07-06T08:56:41+00:00 https://staging.lamerie.com/gprc5d-targeted-drug-modalities-a-chance-for-cure-of-multiple-myeloma/ 2022-07-01T11:14:50+00:00 https://staging.lamerie.com/ror1-targeting-provides-opportunities-for-drug-modalities-with-enhanced-effector-function/ 2022-06-17T09:07:19+00:00 https://staging.lamerie.com/cadherin-17-targeted-novel-drug-modalities-a-target-and-pipeline-review/ 2022-05-20T12:58:00+00:00 https://staging.lamerie.com/claudin-6-a-compelling-target-to-be-addressed-by-effector-enhanced-drug-modalities/ 2022-05-13T09:57:29+00:00 https://staging.lamerie.com/record-sales-of-therapeutic-antibodies-in-2021-pushed-by-immuno-oncology-novel-anti-inflammatory-and-anti-sars-cov-2-antibodies/ 2022-03-16T12:10:50+00:00 https://staging.lamerie.com/targeted-protein-degradation-tpd-by-proteasomal-protacs-molecular-glues-lysosomal-lytacs-and-autophagic-autotacs-or-attecs-provides-plenty-of-opportunities-to-drug-undruggable-targets/ 2022-03-07T10:20:20+00:00 https://staging.lamerie.com/targeted-protein-degradation-tpd-is-emerging-as-a-key-technology-to-overcome-limitations-of-conventional-drug-modalities-and-unlock-the-undrugged-proteome/ 2022-03-07T10:19:22+00:00 https://staging.lamerie.com/prodrug-antibodies-and-cytokines-generated-by-masking-technologies-provide-plenty-of-opportunities-for-founders-investors-and-partnerships/ 2021-10-06T09:42:53+00:00 https://staging.lamerie.com/masked-antibodies-and-cytokines-as-prodrugs-strongly-emerging-novel-technologies-providing-plenty-of-opportunities-for-founders-investors-and-partnerships/ 2021-10-06T09:41:31+00:00 https://staging.lamerie.com/vectorized-antibodies-for-in-vivo-expression-by-dna-and-mrna-an-emerging-new-technology/ 2021-07-01T07:33:31+00:00 https://staging.lamerie.com/landscape-analysis-of-targeted-protein-degradation-by-novel-protacs-and-molecular-glues/ 2020-05-14T15:15:33+00:00 https://staging.lamerie.com/the-growing-field-of-bispecific-t-cell-and-nk-cell-engaging-antibodies-offers-great-opportunities-for-technology-and-product-development-companies/ 2019-06-11T10:35:27+00:00 https://staging.lamerie.com/biologics-sales-reach-another-all-time-high-in-2018-driven-by-innovative-antibodies/ 2019-04-04T09:50:19+00:00 https://staging.lamerie.com/further-record-year-of-biologics-sales-in-2018-due-to-innovative-antibodies/ 2019-04-04T09:09:01+00:00 https://staging.lamerie.com/analysis-and-ranking-of-top-25-pharma-based-healthcare-groups-by-business-segment-for-revenues-sales-rd-costs-and-income/ 2019-01-23T09:14:06+00:00 https://staging.lamerie.com/how-many-pd-1-and-pd-l1-checkpoint-inhibitors-do-we-need/ 2019-01-15T15:19:06+00:00 https://staging.lamerie.com/druggability-of-intracellular-targets-a-challenging-but-highly-rewarded-goal-for-emerging-technologies-to-generate-tcr-fusion-proteins-tcrl-antibodies-and-cell-permeating-biologics/ 2019-01-15T15:09:14+00:00 https://staging.lamerie.com/2016-was-another-record-year-of-biologics-sales-with-therapeutic-antibodies-accounting-for-two-thirds-of-total-biologics-sales/ 2019-01-15T15:05:36+00:00 https://staging.lamerie.com/tcr-engineered-t-cells-are-coming-out-of-the-shadows-and-into-the-light/ 2019-01-15T14:56:29+00:00 https://staging.lamerie.com/all-time-high-of-biologics-sales-in-2017-driven-by-cancer-and-innovative-anti-inflammatory-antibodies/ 2019-01-15T14:53:12+00:00 https://staging.lamerie.com/druggability-of-intracellular-targets-a-challenging-but-highly-rewarded-goal-for-emerging-technologies-to-generate-tcr-fusion-proteins-tcrl-antibodies-and-cell-penetrating-biologics/ 2019-01-15T14:50:44+00:00 https://staging.lamerie.com/670-2/ 2019-01-15T14:47:23+00:00 https://staging.lamerie.com/oncolytic-viruses-a-still-undervalued-technology-with-strong-growth-perspectives/ 2019-01-15T14:43:22+00:00 https://staging.lamerie.com/beyond-anti-cd19-car-t-cells-the-future-of-car-t-cells-depends-on-the-convergence-of-technologies/ 2019-01-15T14:40:44+00:00 https://staging.lamerie.com/strong-emergence-of-t-cell-redirecting-bispecific-antibodies-in-clinical-proof-of-concept-studies/ 2019-01-15T14:38:00+00:00